Platform
Home
Screener
Copilot
AskEdgar Studio
New
Back
Evommune, Inc.
EVMN · SEC Filings
website
48
Evommune, Inc. is a United States-based clinical-stage biotechnology company dedicated to advancing ...
Price
7.65
Market Cap
325.29 M
Float
27.73 M
Country
US
Sector
Healthcare
Exchange
NYSE
Overview
Filings
Insights
Dilution
News
Transcripts
Search in Documents
Open in Studio
Studio
Login
Ask about EVMN
TYPE
HEADLINE
FILED AT
TYPE
HEADLINE
FILED AT
TYPE
HEADLINE
FILED AT
TYPE
HEADLINE
FILED AT
All
Chronological
Financials
Registrations
Prospectus
News
Proxies
Ownerships
Other
Evommune, Inc.
EVMN · SEC Filings
27.73 M
Float
7.65
Price
325.29 M
Market Cap
Financials
TYPE
HEADLINE
FILED AT
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Aug 6, 2026
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
May 7, 2026
10-K
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Mar 5, 2026
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Dec 11, 2025
News
TYPE
HEADLINE
FILED AT
8-K
Evommune to Host Webcast on In-Licensing of Oral VAV1-Directed Molecular Glue Degrader EVO570
Nov 5, 2026
8-K
Evommune In-Licenses Oral VAV1 Molecular Glue Degrader EVO570 from Hinova Pharmaceuticals
Nov 4, 2026
8-K
Evommune Presents Positive Phase 2a Data for EVO301 in Atopic Dermatitis at EADV Congress
Oct 1, 2026
8-K
Evommune Announces Late-Breaker Presentation of Phase 2a Data for EVO301 in Atopic Dermatitis
Sep 23, 2026
8-K
Evommune Corporate Presentation Outlines Pipeline Progress, Clinical Data, and Financial Position
Sep 15, 2026
8-K
Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Atopic Dermatitis and Pipeline Updates
Sep 8, 2026
Prospectus
TYPE
HEADLINE
FILED AT
424B3
UPDATE TO PRIOR PROSPECTUS | Offering amount: $30,000,000 | Shares: 4,966,889 | Price: $6.040 | Bank: Morgan Stanley & Co. LLC
Nov 4, 2026
424B3
UPDATE TO PRIOR PROSPECTUS
Sep 8, 2026
424B3
OFFERING - OTHER
Aug 6, 2026
424B3
OFFERING - OTHER
Jun 29, 2026
424B3
UPDATE TO PRIOR PROSPECTUS
Jun 2, 2026
424B3
OFFERING - OTHER
May 7, 2026
Registrations
TYPE
HEADLINE
FILED AT
S-1
SHARE RESALE REGISTRATION
Apr 17, 2026
S-8
Form S-8 - Securities to be offered to employees in employee benefit plans
Mar 5, 2026
S-8
Form S-8 - Securities to be offered to employees in employee benefit plans
Nov 7, 2025
FWP
Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses
Nov 5, 2025
8-A12B
Form 8-A12B - Registration of securities [Section 12(b)]
Nov 4, 2025
FWP
Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses
Oct 30, 2025
Proxies
TYPE
HEADLINE
FILED AT
DEFA14A
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 21, 2026
DEF 14A
Form DEF 14A - Other definitive proxy statements
Apr 21, 2026
Ownerships
TYPE
HEADLINE
FILED AT
4
Pena Luis C. (Reporting)
Oct 15, 2026
SCHEDULE 13G/A
Andera Partners (Filed by)
Aug 14, 2026
SCHEDULE 13G
PRICE T ROWE ASSOCIATES INC /MD/ (Filed by)
Aug 14, 2026
SCHEDULE 13G
Point72 Asset Management, L.P. (Filed by)
Jul 16, 2026
4
Carver Kyle (Reporting)
Jul 10, 2026
4
KIRSCH ARTHUR S (Reporting)
Jul 8, 2026
Chronological
TYPE
HEADLINE
FILED AT
Other
TYPE
HEADLINE
FILED AT
EFFECT
Form EFFECT - Notice of Effectiveness
Apr 27, 2026
CORRESP
Form CORRESP - Correspondence
Apr 22, 2026
LETTER
Form UPLOAD - SEC-generated letter
Apr 22, 2026
LETTER
Form UPLOAD - SEC-generated letter
Sep 10, 2025
LETTER
Form UPLOAD - SEC-generated letter
Jul 30, 2025
LETTER
Form UPLOAD - SEC-generated letter
Jun 10, 2025
